WallStSmart

Align Technology Inc (ALGN)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Align Technology Inc generates 27% more annual revenue ($4.10B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 10.5%. ALGN appears more attractively valued with a PEG of 0.92. ALGN earns a higher WallStSmart Score of 66/100 (B-).

ALGN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 8.0Quality: 7.0
Piotroski: 4/9Altman Z: 2.76

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALGNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$293.37

Current Price

$167.74

$125.63 discount

UndervaluedFair: $293.37Overvalued
WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$329.71

$171.31 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALGN4 strengths · Avg: 8.5/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.928/10

Growing faster than its price suggests

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
23.9%8/10

Earnings expanding 23.9% YoY

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

ALGN1 concerns · Avg: 4.0/10
P/E RatioValuation
29.4x4/10

Moderate valuation

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALGN

The strongest argument for ALGN centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.92 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : ALGN

The primary concerns for ALGN are P/E Ratio.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

ALGN profiles as a value stock while WST is a growth play — different risk/reward profiles.

ALGN carries more volatility with a beta of 1.67 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

ALGN generates stronger free cash flow (120M), providing more financial flexibility.

Bottom Line

ALGN scores higher overall (66/100 vs 65/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Align Technology Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Align Technology is a manufacturer of 3D digital scanners and the Invisalign clear aligners used in orthodontics. It is headquartered in San Jose, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?